文献速递胃肠外科围术期管理与 ERAS

结直肠手术患者每日一次依诺肝素40mg预防的抗Xa因子水平评估

Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
PubMed 文献 · JAMA Surg · 2019-01-01

这项前瞻性非随机临床试验在2017年2月至2018年7月纳入116例结直肠手术患者,评估每日一次依诺肝素40mg预防时抗Xa因子(aFXa)峰值水平。106例峰值测量合格者中72例(67.9%)抗凝不足(aFXa<0.3 IU/mL),实时剂量调整可使达标率显著提高(85.4% vs 29.2%,P<.001)。

要点

  • 结直肠手术后每日依诺肝素40mg预防,67.9%患者峰值aFXa不达标。
  • 体重与峰值aFXa呈负相关(r²=0.38)。
  • 实时剂量调整较固定剂量显著提高峰值aFXa达标率。

核心结论

  • 大多数结直肠手术患者接受每日一次依诺肝素40mg预防时抗凝不足。
  • 该发现可能解释临床试验中观察到的突破性静脉血栓栓塞事件高发生率。

研究设计与样本

  • 前瞻性非随机临床试验,2017年2月至2018年7月,90天随访,单中心。
  • 纳入全麻下结直肠手术、住院至少3天并接受依诺肝素40mg每日一次的患者116例。
  • 65例女性(56.0%),平均年龄52.1岁(范围18-85岁)。

主要发现

  • 106例(91.4%)峰值aFXa测量合格者中,72例(67.9%)aFXa<0.3 IU/mL。
  • 体重与峰值aFXa呈负相关(r²=0.38)。
  • 实时剂量调整组峰值aFXa达标率85.4%,固定剂量组29.2%(P<.001)。

关键数值与推荐

  • 峰值aFXa目标范围0.3-0.5 IU/mL(依诺肝素40mg/日)。
  • 谷值aFXa目标范围0.1-0.2 IU/mL。

临床怎么用

  • 结直肠手术患者每日依诺肝素40mg预防时,可考虑监测aFXa并实时调整剂量以提高抗凝达标率。

局限性

  • 单中心、非随机设计,样本量有限(116例),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Between 4% and 12% of patients undergoing colorectal surgery and receiving enoxaparin, 40 mg per day, have a postoperative venous thromboembolism (VTE) event. An improved understanding of why "breakthrough" VTE events occur despite guideline-compliant prophylaxis is an important patient safety question. OBJECTIVE: To determine the proportion of patients undergoing colorectal surgery who received adequate anticoagulation based on peak anti-factor Xa (aFXa) levels while receiving enoxaparin at 40 mg per day. DESIGN, SETTING, AND PARTICIPANTS: This prospective, nonrandomized clinical trial was conducted between February 2017 and July 2018 with 90-day follow-up at a quaternary academic medical center in the Intermountain West and included patients undergoing colorectal surgery who had surgery after receiving general anesthesia, were admitted for at least 3 days, and received enoxaparin, 40 mg once daily. INTERVENTIONS: All patients had aFXa levels measured after receiving enoxaparin 40 mg per day. Patients whose aFXa level was out of range entered the trial's interventional arm where real-time enoxaparin dose adjustment and repeated aFXa measurement were performed. MAIN OUTCOMES AND MEASURES: Primary outcome: in-range peak aFXa levels (goal range, 0.3-0.5 IU/mL) with enoxaparin, 40 mg per day. Secondary outcomes: (1) in-range trough aFXa levels (goal range, 0.1-0.2 IU/mL) and (2) the proportion of patients with in-range peak aFXa levels from enoxaparin, 40 mg once daily, vs the real-time enoxaparin dose adjustment protocol. RESULTS: Over 16 months, 116 patients undergoing colorectal surgery (65 women [56.0%]; 99 white individuals [85.3%], 13 Hispanic or Latino individuals [11.2%], and 4 Pacific Islander individuals [3.5%]; mean [range] age, 52.1 [18-85] years) were enrolled. Among 106 patients (91.4%) whose peak aFXa level was appropriately drawn, 72 (67.9%) received inadequate anticoagulation (aFXa < 0.3 IU/mL) with enoxaparin, 40 mg per day. Weight and peak aFXa levels were inversely correlated (r2 = 0.38). Forty-seven patients (77%) had a trough aFXa level that was not detectable (ie, most patients had no detectable level of anticoagulation for at least 12 hours per day). Real-time enoxaparin dose adjustment was effective. Patients were significantly more likely to achieve an in-range peak aFXa with real-time dose adjustment as opposed to fixed dosing alone (85.4% vs 29.2%, P < .001). CONCLUSIONS AND RELEVANCE: This study supports the finding that most patients undergoing colorectal surgery receive inadequate prophylaxis from enoxaparin, 40 mg once daily. These findings may explain the high rate of "breakthrough" VTE observed in many clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02704052.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Pannucci CJ, Fleming KI, Bertolaccini CB, et al. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics. JAMA Surg. 2019. PMID: 31116389. doi:10.1001/jamasurg.2019.1165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。